Making the Rounds on Systemic Mastocytosis Accelerating Diagnosis and Treatment

Mariana C. Castells, MD; Tracy I. George, MD; Patricia L. Lugar,MD; Anne L. Maitland, MD;

This activity is provided by Integritas Communications.



This activity is supported by an educational grant from Blueprint Medicines Corporation.


This activity is endorsed by The Mast Cell Disease Society, Inc.



This program is not certified for continuing education credit. The content and opinions expressed are those of the sponsor and/or presenter(s) and are not necessarily those of the AAAAI.

Program Description 

For this Interactive Showcase™ in nonadvanced systemic mastocytosis (SM), grab your mobile device and headphones for a unique journey through several engaging educational experiences. The first activity, designed as an expert-guided poster tour, will briefly review the pathophysiological drivers of SM and their implications. Subsequently, you will attend a live expert roundtable where faculty will discuss management approaches, including recent clinical trial data on emerging targeted therapies and real-world strategies for comprehensive treatment. During the final activity you will participate in interactive case studies, applying information acquired to real-time management decisions.  

Target Audience 

Clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other clinicians who manage patients with nonadvanced SM. 

Educational Objectives 

  1. Discuss SM pathophysiology, including implications for potential clinical presentations and new targeted therapies 
  2. Evaluate patients with nonadvanced SM to characterize symptoms, disease burdens, and results from ancillary testing 
  3. Discuss recent clinical trial evidence for new targeted treatment options in nonadvanced SM 
  4. Individualize ongoing therapeutic regimens for nonadvanced SM based on symptomatology, patient-reported outcomes, and shared clinical decision making 


Mariana C. Castells, MD, PhD
Director Drug Hypersensitivity and Desensitization Center
Director Mastocytosis Center
Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Tracy I. George, MD
Professor of Pathology
University of Utah School of Medicine
President and Chief Scientific Officer
ARUP Laboratories
Salt Lake City, Utah

Patricia L. Lugar, MD, MS
Section Chief, Allergy and Immunology
Associate Professor of Medicine
Co-Director, Jeffrey Modell Research and Diagnostic Center
Director, Medication Desensitization Program
Duke University Hospital
Durham, North Carolina

Anne L. Maitland, MD, PhD
Allergy/Immunology Specialist, Metrodora Institute
Salt Lake City, Utah
Assistant Clinical Professor, Icahn School of Medicine
Department of Medicine Allergy & Clinical Immunology
New York, New York

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationshipswith ineligible companies:

Mariana C. Castells, MD, PhD: Nothing to disclose

Tracy I. George, MD: Consulting fees: Allakos Inc, Blueprint Medicines Corporation, Bluprint Oncology Concepts, Celgene Corporation, Incyte Corporation, UBC (United BioSource LLC); Contracted Research: Bluepprint Medicines Corporation, Celgene Corporation, Cogent Biosciences, Inc., Deciphera Pharmaceuticals, Inc., Incyte Corporation; all received by ARUP Laboratories

Patricia L. Lugar, MD, MS: Consulting Fee: Blueprint Medicines, Grifols Contracted; Research: BioCryst, BioMarin, Blueprint Medicines, Takeda; Speakers' Bureau: Blueprint Medicines, Grifols

Anne Maitland, MD, PhD: Nothing to disclose

The Integritas Communication planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee to attend this Non-CME Educational Program.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 03/10/2023

type Webcast